神龟加速器是干什么的
Pandect Bioventures identifies transformational healthcare ideas at
the earliest stage, then leverages the knowledge and resources of our rich ecosystem to help build these ideas into successful life science companies.
神龟加速器是干什么的
神龟加速器是干什么的
Our management and executives-in-residence bring decades of experience to our investment picks and portfolio growth.
神龟加速器是干什么的
Founding Executives in Residence
David Spellmeyer, Ph.D.
Krishna Kodukula, Ph.D.
Robert Wild, Ph.D.
Robert Lutz, Ph.D.
神龟加速器是干什么的
Circle Pharma
In 1Q 2024, we co-invested with The Column Group and Nextech Invest in Circle’s Series B. Circle Pharma is developing a new paradigm for cell permeable macrocyclic peptide discovery based on rational design and synthetic chemistry. The Chair of Circle’s SAB, William G. Kaelin Jr. MD (Harvard Medical School/Dana Farber Cancer Institute), received a Nobel Prize in Medicine and Physiology in 2024. For more information, see: www.circlepharma.com.
798安卓加速器破解下载版
2024
上youtube用什么加速器
Oncology
Area of Focus
Macrocycles
Sgreen加速器官网
Private
Location
South San Francisco, CA
Website
circlepharma
798安卓加速器破解下载版
In 2024, we formed an oncology newco at the ShangPharma incubator with a UCSF co-founder, Alan Ashworth PhD/FRS (President of the UCSF Helen Diller Family Comprehensive Cancer Center and Senior Vice President for Cancer Services with UCSF Health), and led the Seed round in 2Q 2024. Azkarra’s mission is to deliver new oncology therapies to patients based on the team’s deep expertise in DNA Damage Response (DDR). For more information, see: www.azkarrabio.com.
Year Invested
2024
Therapeutic Area
Oncology
798安卓加速器破解下载版
DNA Damage Response
上youtube用什么加速器
Private
Location
South San Francisco, CA
Website
azkarrabio
Valitor
In 2024, we co-led Valitor’s Series A with Berkeley Catalyst Fund. Valitor is a biotech spin-out from the University of California, Berkeley (College of Chemistry and Bioengineering Professors Kevin Healy PhD and David Schaffer PhD, both serial entrepreneurs). Valitor has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. For more information, see: www.valitorbio.com.
Year Invested
2024
Therapeutic Area
Ophthalmology
Area of Focus
Multi-Valent Protein Conjugates
Status
Private
Location
Berkeley, CA
Website
valitorbio